RD133
/ IASO BIO
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 27, 2022
Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Tongji Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor • MSLN
1 to 1
Of
1
Go to page
1